# Divi's Laboratories: how the business works

> For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Divi's Laboratories Limited · NSE: DIVISLAB · BSE: 532488 · Sector: Healthcare

Updated for Q2 FY27 · checked 12 Nov 2026

This is the plain-text version of https://cityfort.in/stocks/divis-laboratories. Source ids in [brackets] refer to the list at the end. Credit: "Cityfort, Divi's Laboratories: how the business works", with the page URL.

## In short

Drug companies, mostly in Europe and the Americas, pay Divi's to make medicine ingredients; materials take the biggest share, and ₹23.2 of every ₹100 that came in was left as profit in FY26.

- In FY26 customers in Europe gave 61.0% of Divi's revenue, the Americas 13.2%, India 11.0%, the rest of Asia 10.2% and the rest of the world 4.5% (Cityfort calculation).
- Of every ₹100 that came in during FY26, ₹37.0 went on materials, ₹14.3 on other running costs and ₹13.0 on staff.

## Key facts

**What does Divi's Laboratories do?**

Divi's Laboratories Ltd is a Hyderabad company, incorporated in 1990, that makes active pharmaceutical ingredients (the chemicals in medicines that do the work), intermediates and nutraceutical ingredients. Divi's reported 3 manufacturing facilities and FY26 revenue from operations of ₹10,560 crore. [S1, S42, S9]

**How does Divi's Laboratories make money?**

Divi's Laboratories sells generic drug ingredients to medicine makers and makes ingredients under contract for drug innovators, which it calls custom synthesis. Divi's management said on its Q4 FY26 call (23 May 2026) that custom synthesis was 55% of FY26 sales and generics, including nutraceuticals, 45%; Divi's reports both as one segment. [S19, S1]

**Who are Divi's Laboratories' customers?**

Divi's Laboratories sells mainly to drug companies outside India: in FY26 Europe gave 61.0% of Divi's revenue and the Americas 13.2% (Cityfort calculation from the FY26 annual report). Divi's top five customers gave 51% of FY26 standalone sales. [S1]

**How big is Divi's Laboratories?**

In FY26 Divi's Laboratories earned ₹10,560 crore of revenue and ₹2,568 crore of net profit, up from ₹9,360 crore and ₹2,191 crore in FY25. Divi's reported about 19,300 employees in its FY26 annual report. [S9, S13, S1]

**Who owns Divi's Laboratories?**

On 30 Sep 2026 the promoter group (Divi family members and Divi's Biotech) held 51.88% of Divi's Laboratories, with no shares pledged. Foreign investors held 20.38%, Indian institutions 19.17% and others, including individuals, 8.58%. [S28]

**How did Divi's Laboratories do in Q2 FY27?**

In Q2 FY27 (Jul–Sep 2026) Divi's Laboratories' revenue was ₹3,676 crore, up 35.4% from ₹2,715 crore in Q2 FY26, and net profit was ₹1,127 crore, up 63.6% from ₹689 crore. [S6, S11]

**Does Divi's Laboratories have debt?**

Divi's Laboratories had no borrowings on 30 Sep 2026 and ₹2,236 crore of cash and bank balances, down from ₹3,414 crore on 31 Mar 2026 (Cityfort calculation from the results filings). CARE rated Divi's bank facilities AA+ (Stable) on 26 Aug 2025. [S6, S9, S40]

**What dividend does Divi's Laboratories pay?**

Divi's Laboratories paid a dividend of ₹30 a share for each year from FY22 to FY26; the FY26 dividend came to ₹796 crore. [S1, S2, S3, S4, S5, S6]

**Who runs Divi's Laboratories?**

Dr Murali K. Divi, the promoter, is managing director of Divi's Laboratories. Dr Kiran S. Divi is whole-time director and CEO, and Venkatesa Perumallu Pasumarthy has been chief financial officer since 1 Aug 2025. [S1, S56, S55]

## What does Divi's Laboratories sell?

Divi's makes the chemical ingredients that go into medicines, not the tablets themselves. It sells off-patent ingredients to medicine makers, and makes ingredients to order for drug innovators. It also sells nutraceutical ingredients, such as vitamins.

- **Generic drug ingredients (APIs):** Active pharmaceutical ingredients (APIs), the chemicals in a medicine that do the work, for medicines whose patents have expired. CARE names naproxen (for arthritis pain), dextromethorphan, levodopa, gabapentin and nabumetone among them. Management said on its Q4 FY26 call (23 May 2026) that generics, including nutraceuticals, were 45% of FY26 sales. [S40, S19, S1]
- **Custom synthesis for drug innovators:** Drug innovators hire Divi's to make APIs and intermediates (part-made ingredients) for their own medicines, from trials to commercial supply. Divi's says it is a partner to 12 of the top 20 pharmaceutical companies. Management said on its Q4 FY26 call (23 May 2026) that custom synthesis was 55% of FY26 sales. [S1, S18, S19]
- **Nutraceutical ingredients:** Ingredients for human health, animal health and dietary supplements, with over 100 offerings, Dr Kiran S. Divi said in Aug 2026. Management said nutraceutical sales were ₹946 crore in FY26, about 9.0% of revenue (Cityfort calculation). [S18, S19, S9]
- **Peptides (new):** Building blocks and fragments for peptide medicines, chains of amino acids. Divi's set up a Peptide Centre of Excellence in FY26 and is adding solid- and liquid-phase peptide capacity. [S1, S18]

## Who pays Divi's Laboratories?

- **Customers in Europe (61.0% of revenue):** Drug companies in Europe: ₹6,446 crore of FY26 revenue, grouped by where products and services are delivered. Switzerland alone was ₹2,611 crore. Shares are Cityfort calculations from the FY26 revenue by region. [S1]
- **Customers in the Americas (13.2% of revenue):** ₹1,397 crore in FY26. The US alone was ₹1,092 crore, down from ₹1,306 crore in FY25. [S1]
- **Customers in India (11.0% of revenue):** ₹1,159 crore in FY26, including ₹12 crore of export incentives. [S1]
- **Customers in the rest of Asia (10.2% of revenue):** ₹1,079 crore in FY26. [S1]
- **Customers in the rest of the world (4.5% of revenue):** ₹479 crore in FY26. [S1]
- **Customer concentration:** top 5 51.0% of revenue. Divi's top five customers gave 51% of FY26 standalone sales, up from 49% in FY25 and 37% in FY24; its top five products gave 48%. Divi's does not name its customers or give the largest customer's share. [S1, S3, S54]

## Where the money went (FY26)

1. In FY26 Divi's sold ₹10,560 crore of ingredients and earned ₹507 crore of other income.
2. Materials took ₹4,093 crore and employees ₹1,442 crore.
3. Other running costs took ₹1,584 crore, and depreciation and interest ₹486 crore.
4. A one-off labour-code charge took ₹74 crore and income tax ₹820 crore.
5. What was left was ₹2,568 crore of net profit.

Sources: S9, S1, S10, S20, S19.

## Key numbers by year (₹ crore)

Financials: consolidated, ₹ crore. Financial year runs April to March (March year end). — = not shown on the page.

| Year | Revenue | EBITDA | EBITDA margin | Net profit | Net margin | EPS (₹ per share) | Operating cash flow | Capital spending | Free cash flow | Sources |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| FY22 | 8,960 | 3,882 | 43.3% | 2,960 | 33.0% | 111.52 | 1,912 | 713 | 1,199 | S17, S5 |
| FY23 | 7,768 | 2,368 | 30.5% | 1,823 | 23.5% | 68.69 | 2,460 | 473 | 1,987 | S16, S4 |
| FY24 | 7,845 | 2,205 | 28.1% | 1,600 | 20.4% | 60.27 | 1,261 | 1,003 | 258 | S15, S3 |
| FY25 | 9,360 | 2,968 | 31.7% | 2,191 | 23.4% | 82.53 | 1,653 | 1,438 | 215 | S13, S2 |
| FY26 | 10,560 | 3,367 | 31.9% | 2,568 | 24.3% | 96.75 | 2,738 | 2,520 | 218 | S9, S1 |

- EBITDA = profit before interest, tax and wear-and-tear of assets.
- Net profit is the share belonging to the company's owners.

## Balance sheet (as of 30 Sep 2026, ₹ crore)

On 30 Sep 2026 Divi's had no borrowings and ₹2,236 crore of cash and bank balances, down from ₹3,414 crore on 31 Mar 2026 (Cityfort calculation from the results filings). [S6, S9, S11, S1, S18, S19]

| Item | Value |
| --- | --- |
| Total debt | 0 |
| Cash and investments | 2,236 |
| Net debt (debt minus cash) | −2,236 |
| Net worth (shareholders' money) | 17,997 |
| Debt to equity (times) | 0 |

- In H1 FY27 operating cash flow was ₹384 crore (₹1,645 crore in H1 FY26), against ₹872 crore spent on plants and equipment and ₹797 crore of dividends paid.
- Inventories rose from ₹3,954 crore on 31 Mar 2026 to ₹5,540 crore on 30 Sep 2026, and trade receivables from ₹2,984 crore to ₹3,487 crore. Nilima Prasad Divi said on 1 Aug 2026 that Divi's kept strategic inventory buffers given supply risks linked to West Asia.
- Cash and bank balances = cash and equivalents plus other bank balances; Divi's held no current investments. Management said on the Q4 FY26 call (23 May 2026) that cash and cash equivalents stood at ₹3,414 crore on 31 Mar 2026, the same as our figure.
- A ₹456 crore refundable advance from a customer (31 Mar 2026) is not counted as borrowing. Lease liabilities were ₹7 crore on 31 Mar 2026.

## Who owns Divi's Laboratories? (shareholding, Q2 FY27)

| Holder | % of shares |
| --- | --- |
| Promoters | 51.88% |
| Promoter shares pledged (% of promoter shares) | 0.0% |
| Foreign institutions (FII) | 20.38% |
| Indian institutions (DII) | 19.17% |
| Public | 8.58% |

Sources: S39, S38, S37, S36, S35, S34, S33, S32, S31, S30, S29, S28.

## What could go wrong

### A few customers and products

Divi's top five customers gave 51% of FY26 standalone sales, up from 37% in FY24, and its top five products 48%. CARE said top-five product concentration above 60% could lead to a rating action. [S1, S3, S40]

What to watch: Top-five customer and product shares in the FY27 annual report.

### Lumpy custom work

Management said custom synthesis was 59% of sales in FY22, 44% in FY23, 45% in FY24 and 55% in FY26. Revenue fell 13.3% in FY23. Nilima Prasad Divi said on 1 Aug 2026: "as we always said, there is lumpiness". [S27, S26, S25, S19, S16, S17, S18]

What to watch: The custom synthesis share and revenue in each quarter.

### Cash tied up in stock

Inventories rose from ₹3,954 crore to ₹5,540 crore between 31 Mar and 30 Sep 2026. H1 FY27 operating cash flow of ₹384 crore was below capital spending of ₹872 crore, and cash and bank balances fell to ₹2,236 crore. [S9, S6]

What to watch: Inventories and operating cash flow in the FY27 results.

### Regulator approvals for plants

Customers rely on plants passing inspections by the US FDA and others. A 2024 Unit 2 inspection ended with one procedural observation, and Unit 1's Nov 2025 inspection with none. Management said in Aug 2026 the US FDA may take 1 or 2 years to qualify Kakinada. [S49, S48, S18]

What to watch: US FDA inspection outcomes, filed with the exchanges.

### Currency moves

Exports were 89% of FY26 standalone sales, and 86% of exports were in US dollars. Forex gains in other income were ₹24 crore in Q2 FY27, against ₹63 crore in Q2 FY26. [S1, S7]

What to watch: The rupee against the US dollar and the forex line in each results filing.

### Raw material and solvent costs

Imports were 44% of FY26 standalone materials. Nilima Prasad Divi said on 1 Aug 2026 that solvent costs rose, and that West Asia added uncertainty to supply chains. [S1, S18, S6]

What to watch: Materials as a share of revenue each quarter (32.1% in Q2 FY27).

### Tax disputes

A draft income-tax order proposes ₹570.51 crore of additions for AY 2023-24, with penalty proceedings for alleged under-reporting to be started separately. A GST demand totals ₹249 crore. Divi's says liability in both is remote. [S50, S1, S51]

What to watch: The Dispute Resolution Panel's decision and the Telangana High Court case.

### New capacity on time

Capital work in progress was ₹1,638 crore on 30 Sep 2026. The ₹650–700 crore dedicated facility was expected around Jan 2027, and new plants need customer and regulator validation before supply starts. [S6, S45, S18]

What to watch: Any filing on the start of the dedicated facility.

## What to watch

Next: Q3 FY27 results, Date not announced yet.

- **Dedicated facility start:** Divi's said in Apr 2024 the ₹650–700 crore facility was expected around Jan 2027; on 1 Aug 2026 Dr Kiran S. Divi said three major capex programmes were nearing completion, with validations going on.
- **Inventory and cash:** Inventories were ₹5,540 crore and cash and bank balances ₹2,236 crore on 30 Sep 2026, against ₹3,954 crore and ₹3,414 crore on 31 Mar 2026.
- **Business mix:** Whether a Q2 FY27 call is filed with the custom synthesis share; management said it was 60% of standalone sales in Q1 FY27.

## Sources

- S1: 36th Annual Report 2025-26 (FY26). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_29804_DIVISLAB_2025_2026_A_23371989_15072026143537.pdf (published 15 Jul 2026)
- S2: 35th Annual Report 2024-25 (FY25). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_26906_DIVISLAB_2024_2025_A_14072025175449.pdf (published 14 Jul 2025)
- S3: 34th Annual Report 2023-24 (FY24; company website copy, the NSE copy is truncated). Divi's Laboratories Ltd. https://www.divislabs.com/wp-content/uploads/2025/07/Annual-Report-2023-24-Divis-Laboratories-Limited.pdf (published 15 Jul 2024)
- S4: 33rd Annual Report 2022-23 (FY23; NSE zip). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_22614_DIVISLAB_2022_2023_02082023165735_08022023170003.zip (published 2 Aug 2023)
- S5: 32nd Annual Report 2021-22 (FY22; NSE zip). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/annual_reports/AR_20473_DIVISLAB_2021_2022_25072022101931_07252022110002.zip (published 25 Jul 2022)
- S6: Consolidated financial results Q2 FY27 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1755425_07112026045655_WEB.xml (published 7 Nov 2026)
- S7: Outcome of board meeting 7 Nov 2026: Q2 FY27 standalone and consolidated results, limited review reports and press release. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_07112026115520_Outcome_BoardMeeting_07112026_DivisLabs.pdf (published 7 Nov 2026)
- S8: Consolidated financial results Q1 FY27 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1706514_01082026010514_WEB.xml (published 1 Aug 2026)
- S9: Consolidated financial results Q4 FY26 and FY26 (revised filing 27 May 2026: quarter start date corrected) (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1674093_27052026053820_WEB.xml (published 27 May 2026)
- S10: Consolidated financial results Q3 FY26 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1623134_11022026021620_WEB.xml (published 11 Feb 2026)
- S11: Consolidated financial results Q2 FY26 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1568213_07112025055857_WEB.xml (published 7 Nov 2025)
- S12: Consolidated financial results Q1 FY26 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1503709_06082025124854_WEB.xml (published 6 Aug 2025)
- S13: Consolidated financial results Q4 FY25 and FY25 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INTEGRATED_FILING_INDAS_1442335_17052025063735_WEB.xml (published 17 May 2025)
- S14: Consolidated financial results Q3 FY25 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_118476_1369222_03022025051211.xml (published 3 Feb 2025)
- S15: Consolidated financial results Q4 FY24 and FY24 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_107240_1139127_25052024050847.xml (published 25 May 2024)
- S16: Consolidated financial results Q4 FY23 and FY23 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_92223_847945_20052023055615.xml (published 20 May 2023)
- S17: Consolidated financial results Q4 FY22 and FY22 (no balance sheet in this filing) (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/INDAS_85099_658738_23052022052209_WEB.xml (published 23 May 2022)
- S18: Earnings call transcript Q1 FY27 (call 1 Aug 2026). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_06082026142802_Transcript_Concall_01082026.pdf (published 6 Aug 2026)
- S19: Earnings call transcript Q4 FY26 (call 23 May 2026). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_29052026103543_Q4FY26_Transcript_of_EarningsCall23052026.pdf (published 29 May 2026)
- S20: Earnings call transcript Q3 FY26 (call 11 Feb 2026). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_14022026152125_Transcript_earningsCall_11022026.pdf (published 14 Feb 2026)
- S21: Earnings call transcript Q2 FY26 (call 7 Nov 2025). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_12112025171749_Transcript_of_Q2FY26EarningsCall_07112025.pdf (published 12 Nov 2025)
- S22: Earnings call transcript Q1 FY26 (call 6 Aug 2025). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_12082025092309_Transcript_Q1FY26_EarningsConferenceCall_06082025.pdf (published 12 Aug 2025)
- S23: Earnings call transcript Q4 FY25 (call 17 May 2025). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_23052025160038_Transcript_Q4FY25Earnings_Call_17052025_DivisLab.pdf (published 23 May 2025)
- S25: Earnings call transcript Q4 FY24 (call 25 May 2024). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_30052024162432_Submission_Transcript_Concall_25052024.pdf (published 30 May 2024)
- S26: Earnings call transcript Q4 FY23 (call 20 May 2023). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_25052023161622_Transcript_EarningsCall_Q4FY23_20052023.pdf (published 25 May 2023)
- S27: Earnings call transcript Q4 FY22 (call 23 May 2022). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_26052022122000_Earnings_Call_Transcript_Q4FY22_DivisLab.pdf (published 26 May 2022)
- S28: Shareholding pattern as of 30 Sep 2026 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1733233_06102026103802_WEB.xml (published 6 Oct 2026)
- S29: Shareholding pattern as of 30 Jun 2026 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1695062_17072026025119_WEB.xml (published 17 Jul 2026)
- S30: Shareholding pattern as of 31 Mar 2026 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1650975_15042026085225_WEB.xml (published 15 Apr 2026)
- S31: Shareholding pattern as of 31 Dec 2025 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1597165_09012026110757_WEB.xml (published 9 Jan 2026)
- S32: Shareholding pattern as of 30 Sep 2025 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1545060_11102025123909_WEB.xml (published 11 Oct 2025)
- S33: Shareholding pattern as of 30 Jun 2025 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_1486018_18072025093330_WEB.xml (published 18 Jul 2025)
- S34: Shareholding pattern as of 31 Mar 2025 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_197933_1418219_18042025121732_WEB.xml (published 18 Apr 2025)
- S35: Shareholding pattern as of 31 Dec 2024 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_195156_1349647_17012025052059_WEB.xml (published 17 Jan 2025)
- S36: Shareholding pattern as of 30 Sep 2024 (revised filing 7 Nov 2024) (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_191610_1266253_11102024034546_WEB.xml (published 7 Nov 2024)
- S37: Shareholding pattern as of 30 Jun 2024 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_190061_1191952_18072024045956_WEB.xml (published 18 Jul 2024)
- S38: Shareholding pattern as of 31 Mar 2024 (revised filing 4 Jun 2024) (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_186639_1152456_04062024113717_WEB.xml (published 4 Jun 2024)
- S39: Shareholding pattern as of 31 Dec 2023 (XBRL). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/xbrl/SHP_183511_1012462_09012024043904_WEB.xml (published 9 Jan 2024)
- S40: CARE Ratings press release: Divi's Laboratories Limited (bank facilities reaffirmed CARE AA+; Stable / CARE A1+). CARE Ratings Ltd. https://www.careratings.com/upload/CompanyFiles/PR/202508130856_Divis_Laboratories_Limited.pdf (published 26 Aug 2025)
- S41: Intimation of reaffirmation of credit rating by CARE (13 Sep 2024). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_14092024145420_Intimation_Credit_rating_Reaffirmation.pdf (published 14 Sep 2024)
- S42: Business Responsibility and Sustainability Report 2025-26. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_15072026172351_BRSR2025_26_DivisLabs.pdf (published 15 Jul 2026)
- S43: NSE equity bhavcopy, 11 Nov 2026 (DIVISLAB close). National Stock Exchange of India. https://nsearchives.nseindia.com/content/cm/BhavCopy_NSE_CM_0_0_0_20261111_F_0000.csv.zip (published 11 Nov 2026)
- S44: Commencement of commercial operations at part of Phase I of Unit III, Kakinada (from 1 Jan 2025). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_02012025151714_Reg_30_-_Intimation_Unit_3_commencement.pdf (published 2 Jan 2025)
- S45: Information about proposed capacity addition (₹650–700 crore, long-term supply agreement). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_25042024105245_Reg30_capacityaddition_DivisLab_25042024.pdf (published 25 Apr 2024)
- S46: Signing of long-term manufacturing and supply agreement with a global pharma company (advanced intermediates). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_18042025074505_Reg30_Longterm_SupplyAgreement_18042025.pdf (published 18 Apr 2025)
- S47: Signing of a second long-term manufacturing and supply agreement with a global pharma company (advanced intermediates). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_24052025090730_Reg30_Signing_Longterm_SupplyAgreement_24052025.pdf (published 24 May 2025)
- S48: US-FDA inspection of Unit-I (10–14 Nov 2025) concluded with no 483 observations. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_14112025155146_Reg_30_Intimation_of_outcome_of_Unit_I_USFDA_audit.pdf (published 14 Nov 2025)
- S49: US-FDA inspection of Unit-II (11–19 Jul 2024): one procedural observation. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_19072024131324_Regulation30Intimation_USFDA_Inspection.pdf (published 19 Jul 2024)
- S50: Draft assessment order under section 144C(1), Income Tax Act, AY 2023-24 (additions of ₹570.51 crore proposed). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_21032026160840_Reg30_Intimation_21032026.pdf (published 21 Mar 2026)
- S51: GST order on IGST refund (demand ₹82.04 crore plus equal penalty and interest). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_16112023111558_Regulation30_intimation_16112023.pdf (published 16 Nov 2023)
- S52: Update on GST order: writ petition filed, interim order (10% deposit, no coercive action). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_03012024145556_Intimation_update_on_GST_Order_03012024.pdf (published 3 Jan 2024)
- S53: Enforcement Directorate order: FEMA penalty of ₹6 lakh each on the company and its CEO (late Annual Performance Reports). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_04122024102757_Regulation_30_intimation.pdf (published 4 Dec 2024)
- S54: Clarification on news item (US court ruling on a Novartis generic): company supplies under agreements and cannot comment. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_05122024135057_Regulation_30NewsClarification_05122024.pdf (published 5 Dec 2024)
- S55: Board outcome 17 May 2025: CFO L. Kishore Babu superannuates, Venkatesa Perumallu Pasumarthy appointed CFO. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_17052025134432_Outcome_Board_Meeting_Q42025_17052025.pdf (published 17 May 2025)
- S56: Board outcome 3 Feb 2025: re-appointment of Dr. Kiran S. Divi as Whole-time Director and CEO for 5 years. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_03022025131025_Outcome_BoardMeetingQ3FY25.pdf (published 3 Feb 2025)
- S57: Board outcome 7 Nov 2025: N.V. Anirudh designated President (Nutraceuticals), senior management. Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_07112025120843_Outcome_BoardMeeting_07112025.pdf (published 7 Nov 2025)
- S60: Intimation about manufacturing of Molnupiravir API (MSD authorised manufacturer). Divi's Laboratories Ltd (filed with NSE). https://nsearchives.nseindia.com/corporate/DIVISLAB_26052021125413_SEIntimation26052021_DivisLab.pdf (published 26 May 2021)
